Memorial Sloan Kettering Cancer Center Leads Phase 2 Study Testing mRNA-based Pancreatic Cancer Vaccine

A recent study titled &ldquo;A Phase II, Open-Label, Multicenter, Randomized Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFolfirinox Versus mFolfirinox Alone in Patients with Resected Pancreatic Ductal Adenocarcinoma&rdquo; involved one of America&rsquo;s most prominent oncology-focused cancer trial sites&mdash;Memorial Sloan Kettering Cancer Center (MSKCC). TrialSite has emphasized the vital importance of diversification into cancer therapies for mRNA developers such as BioNTech, one of the industry sponsors of this study. The Germany company partners with Genentech, part of the Roche family of companies. 
The Study